Skip to content

Artificial Intelligence Scalable Solution for ST Myocardial Infarction

Artificial Intelligence Scalable Solution for ST Myocardial Infarction (ASSIST): Cross-sectional Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06939738
Acronym
ASSIST
Enrollment
489
Registered
2025-04-23
Start date
2025-04-01
Completion date
2026-06-30
Last updated
2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction (AMI)

Keywords

Acute Myocardial Infarction (AMI), STEMI, NSTEMI, Occlusion Myocardial Infarction (OMI), AI-based ECG analysis

Brief summary

The ASSIST clinical study is an observational, multicenter study to assess the performance of a cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, developed to detect Acute Myocardial Infarction (AMI). The main objectives are to compare Willem™ performance to detect and triage ECG patterns associated with AMI compared with human ECG interpretation, and to assess the time periods for both approaches.

Detailed description

Delays in triage and diagnosis of patients presented with chest pain or other symptoms suggestive of Acute coronary syndrome (ACS) can be fatal. This study aims to improve those two aspects in acute ischemic disease care: reducing the delays to intervention and improving the accuracy of initial diagnosis, which are of paramount importance in cases of ACS, especially in ST-elevation myocardial infarction (STEMI). The former plays a critical role in minimizing in-hospital mortality rates, which have been shown to decrease proportionally with reduction of times to intervention. The latter relies on a correct interpretation of the ECG, first-line diagnostic tool in the assessment of patients with suspected ACS. The current standard of care for ACS includes a 12-lead ECG that should be performed within the first 10 minutes from the first medical contact. The ECG must be interpreted by a qualified physician, who will alert the on-call cardiologist to confirm or not the activation of the "infarction code", based on the ECG and clinical presentation. Such activation will mainly entail immediate transfer of the patient to the nearest hospital with the possibility of emergency coronary angiography (if not present in the initial institution), and eventual percutaneous coronary intervention (PCI). Regarding the diagnosis of Acute Myocardial Infarction (AMI), an accurate and rapid interpretation of the first ECG is critical for the differential diagnosis between STEMI, NSTEMI or unstable angina; and follow the proper standard of care guidelines. The largest delays occurs between the first ECG and the transportation for the cardiac catheterization laboratory, which has prognostic implications. In recent years, automatic digital tools based on artificial intelligence (AI) have been proposed as a solution to support physicians in the ECG interpretation, reducing their workload and time-to-diagnosis, suggesting the beneficial impact of AI-platforms for accurate diagnosis of AMI. In this setting, the AI-platforms should be able to automatically detect ECG patterns linked to unfavorable coronary anatomy and poor outcomes. It is also essential to have the capacity to identify more subtle ECG patterns, not obvious during physicians' interpretation, but indicating high-risk coronary anatomy. Additionally, the platform should assist the prediction of most severe coronary lesions, especially obstructive stenosis. This ability to detect coronary lesions could be useful in preventing unnecessary or premature activation of the catheterization laboratory, mainly in NSTEMI setting. The ASSIST clinical study is a cross-sectional, multicenter study aiming to collect data to develop the Willem™ platform, an AI-based tool for ECG analysis. This plataform could improve the accuracy for AMI diagnosis, particularly the differentiation between STEMI and NSTEMI, and early identification of patients with Occlusion Myocardial Infarction (OMI).

Interventions

None listed

Sponsors

Idoven 1903 S.L.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years; * Available digitally stored 12-lead ECG traces prior to invasive coronary angiography; * Available angiographic and clinical data.

Exclusion criteria

* ECGs with poor signal quality; * Lack of digitally stored 12-lead ECG traces prior to coronary angiography; * Previous coronary events (AMI, coronary revascularizations); * Non-available clinical or angiographic data.

Design outcomes

Primary

MeasureTime frameDescription
Device performanceAt the time of enrolment and throughout the baseline visit (single study visit)Assessment of Willem™ diagnostic performance to detect Acute Myocardial Infarction (AMI) based on ECG analysis. The diagnostic performance metrics and their measurement units will be: * Accuracy, Sensitivity, and Specificity (%) * Positive Predictive Value (PPV) and Negative Predictive Value (NPV) (%) * F1-score (score from 0.0 to 1.0)

Secondary

MeasureTime frameDescription
Time assessmentAt the time of enrolment and throughout the baseline visit (single study visit)Assessment of the time needed for AMI diagnosis and for intervention (e.g. door-to-balloon time)

Countries

Portugal, Spain

Contacts

PRINCIPAL_INVESTIGATORAlfonso Jurado, MD, PhD

La Paz University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 21, 2026